IDEAYA Biosciences, Inc.
IDYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7 | $23 | $51 | $28 |
| % Growth | -70.1% | -54.1% | 82.3% | – |
| Cost of Goods Sold | $4 | $4 | $2 | $2 |
| Gross Profit | $3 | $19 | $49 | $26 |
| % Margin | 45.2% | 82.9% | 95.9% | 93.8% |
| R&D Expenses | $295 | $130 | $90 | $58 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $35 | $24 | $22 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $330 | $154 | $111 | $76 |
| Operating Income | -$327 | -$134 | -$63 | -$50 |
| % Margin | -4,671.1% | -574.9% | -122.7% | -179.9% |
| Other Income/Exp. Net | $52 | $21 | $4 | $1 |
| Pre-Tax Income | -$274 | -$113 | -$59 | -$50 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$274 | -$113 | -$59 | -$50 |
| % Margin | -3,921.1% | -483% | -115.2% | -178.1% |
| EPS | -3.36 | -1.96 | -1.42 | -1.41 |
| % Growth | -71.4% | -38% | -0.7% | – |
| EPS Diluted | -3.36 | -1.96 | -1.42 | -1.41 |
| Weighted Avg Shares Out | 82 | 58 | 41 | 35 |
| Weighted Avg Shares Out Dil | 82 | 58 | 41 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $52 | $21 | $4 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4 | $4 | $2 | $2 |
| EBITDA | -$271 | -$109 | -$57 | -$48 |
| % Margin | -3,866.3% | -465.9% | -111% | -171.9% |